Ascelia Pharma AB
STO:ACE

Watchlist Manager
Ascelia Pharma AB Logo
Ascelia Pharma AB
STO:ACE
Watchlist
Price: 4.5 SEK 5.76% Market Closed
Market Cap: 522.1m SEK

Relative Value

There is not enough data to reliably calculate the relative value of ACE.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ACE Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.3
Forward
6.1
vs History
vs Industry
Median 3Y
-9.5
Median 5Y
-15.8
Industry
23.3
Forward
-37.1
vs History
vs Industry
Median 3Y
-8.2
Median 5Y
-15.1
Industry
19.8
vs History
vs Industry
Median 3Y
-11.9
Median 5Y
-16.4
Industry
22.6
vs History
71
vs Industry
26
Median 3Y
9.2
Median 5Y
9.9
Industry
2.7
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.6
Forward
5.5
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.4
vs History
vs Industry
Median 3Y
-9.2
Median 5Y
-14.6
Industry
4.7
Forward
29.4
vs History
vs Industry
Median 3Y
-9.2
Median 5Y
-14.6
Industry
4.8
Forward
29.4
vs History
vs Industry
Median 3Y
-8
Median 5Y
-13.9
Industry
5.3
vs History
vs Industry
Median 3Y
-8
Median 5Y
-13.9
Industry
3.8
vs History
74
vs Industry
37
Median 3Y
15.7
Median 5Y
26.4
Industry
5

Multiples Across Competitors

ACE Competitors Multiples
Ascelia Pharma AB Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Ascelia Pharma AB
STO:ACE
522.1m SEK 0 -6.1 -6.5 -6.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 706 744.2 -160 203.2 -194 537.7 -192 317.8
US
Abbvie Inc
NYSE:ABBV
334.3B USD 5.8 80.5 15.3 22.6
US
Amgen Inc
NASDAQ:AMGN
160.4B USD 4.7 27 14.5 23.9
US
Gilead Sciences Inc
NASDAQ:GILD
139.1B USD 4.8 23.3 10.1 14
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.1B USD 10.6 -119.4 25.4 26.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 090.1 -533.3 -580.7 -565.3
AU
CSL Ltd
ASX:CSL
117.5B AUD 5.1 28 17.3 21.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.2B USD 4.2 13.2 11.8 13.2
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.7 -66.6 -60.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
43.3B USD 18.4 -160.4 -720.3 -361
P/S Multiple
Revenue Growth P/S to Growth
SE
Ascelia Pharma AB
STO:ACE
Average P/S: 3 370 890.8
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 706 744.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.8
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.6
10%
1.1
US
E
Epizyme Inc
F:EPE
2 090.1
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.2
4%
1.1
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
18.4
29%
0.6
P/E Multiple
Earnings Growth PEG
SE
Ascelia Pharma AB
STO:ACE
Average P/E: 34.4
Negative Multiple: -6.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 203.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
80.5
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
27
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.3
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -119.4 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.3 N/A N/A
AU
CSL Ltd
ASX:CSL
28
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.2
7%
1.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -160.4 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SE
Ascelia Pharma AB
STO:ACE
Average EV/EBITDA: 15.7
Negative Multiple: -6.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 537.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.3
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.5
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.4
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580.7 N/A N/A
AU
CSL Ltd
ASX:CSL
17.3
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.8
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -720.3 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
Ascelia Pharma AB
STO:ACE
Average EV/EBIT: 20.3
Negative Multiple: -6.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 317.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.6
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.9
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
14
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.6
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.3 N/A N/A
AU
CSL Ltd
ASX:CSL
21.6
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.2
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -361 N/A N/A